AccuDial expands board of directors
PALM BEACH GARDENS, Fla. AccuDial Pharmaceutical on Wednesday announced the expansion of its board of directors by five executives.
New board member appointments include:
- Schuyler Jungen Baab — president and CEO of Pathfinders Government Relations, a government relations consulting practice in Washington. Baab previously served as deputy under-secretary of the Department of Health and Human Services.
- Stephen Key — a successful inventor and entrepreneur with more than 20 licensed products in the past 30 years. Key’s rotating label is the patented technology that AccuDial Pharmaceutical has licensed for its weight-based dosing of liquid medications.
- Patrick Lonergan — formerly a 30-year veteran with Johnson & Johnson, where he held a number of leadership positions, including VP and general manager. While at Johnson & Johnson, he served as a member of the board of directors of Johnson & Johnson Products and was chairman of the Health Care Division Management Committee. Lonergan also has served as vice chairman of the board of the Consumer Healthcare Products Association, business chairman for the National Association of Chain Drug Stores and chairman of the National Wholesale Druggists’ Association Industry Development Committee. He is the co-founder of Numark Labs and has served as its president since January 1989.
- Christopher Metz — a managing director of Sun Capital Partners, a private investment firm in South Florida with approximately $8 billion of equity capital under management. Prior to joining Sun Capital Partners, Metz was president of the Hardware and Home Improvement Group of Black & Decker, holding several senior positions during his 13-year tenure. Metz also was president of Kwikset Corp. and Price Pfister, and was general manager of European Professional Power Tools and Accessories.
- Matthew O’Connor — served as president/partner for USI Florida and was the founding partner of several successful start-ups, including the North Broward School, which was sold in 2005 to Wall Street investment firm Sterling Capital to launch Ameritas Schools International. As president of AMG Enterprises, O’Connor leads boutique real estate development projects on coastal properties.
“It is truly a privilege for a relatively new pharmaceutical company such as AccuDial to have the counsel of five seasoned executives with incomparable industry experience,” stated Robert Terwilliger, president, chairman and CEO of AccuDial. “We look forward to working with them and the rest of our board members to pursue the dynamic growth opportunities and expansion of AccuDial’s products — from OTC medications to prescription and institutional, as well as veterinary applications.”
Proantinox may reduce UTI incidence in women, study suggests
EDISON, N.J. A recent study being published in the journal Urology found that Proantinox, a proprietary cranberry-based blend found in DSE Healthcare Solutions’ Cystex liquid cranberry complex with Proantinox, is safe and effective in significantly reducing the incidence of urinary tract infections in women at risk for recurring infections.
The study, conducted by Aaron Katz, professor of clinical urology at Columbia University college of physicians and surgeons, also found that those women who took the recommended doses of the formula significantly improved quality of life as measured by the American Urological Association Symptom Index.
“The objectives of this study initially were to determine the safety, tolerability and maximum dose necessary of the proprietary Proantinox formula, but the secondary finding of efficacy was so significant, we felt it was worth noting,” stated Katz. “Normally you would expect at least 32% to 36% of the participants, based on history, to have at least one more infection or UTI symptoms during the study period, but we found only 9% of the sample had this occur.”
The study looked at 28 women, ages 18 to 75 years, who had experienced at least two or more urinary tract infections in the past six months. In addition to the tolerability and efficacy findings, questionnaires were also completed at baseline, week four and week 12 to measure overall health and quality of life based on the AUA Symptom Index.
Perrigo gains OTC rights for generic Allegra products
ALLEGAN, Mich. Perrigo on Tuesday announced that it has acquired the exclusive U.S. store brand rights to sell and distribute OTC versions of fexofenadine HCl 180 mg and 60 mg tabs, plus fexofenadine HCl 60 mg and pseudoephedrine 120 mg tabs, the generic versions of Sanofi-Aventis’ Allegra and Allegra D-12 products, respectively.
Allegra 180 mg, 60 mg, and Allegra D-12 are indicated for the relief of symptoms associated with seasonal allergies. Sanofi-Aventis has applied to the Food and Drug Administration for the Rx-to-OTC switch of these drugs, even going so far as to acquire OTC supplier Chattem as an in-house distribution arm for the allergy medicine.
It is assumed Allegra will be approved for its switch OTC, especially as an FDA advisory committee in 2001 recommended Allegra be eligible for switch.
Prior to generic competition entering the fexofenadine Rx market in 2005, Allegra 180 mg and 60 mg had combined annual sales of approximately $1.5 billion, and in 2009, Allegra D-12 had annual sales of $600 million according to data provided by Wolters-Kluwer.